ArticleOncogene2019
Targeting the Achilles' heel of cancer cells via integrin-mediated delivery of ROS-generating dihydrolipoamide dehydrogenase.
Article in Oncogene, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 65 citations in OpenAlex.
- Titanium Dioxide in Biomedical and Environmental Nanotechnology: From Photocatalytic Detoxification to Targeted Therapeutics.Molecules (Basel, Switzerland) · 2026Review
- A Multifunctional Molecular Probe for Multimodal Imaging-Guided Potent Photothermal/Photodynamic Therapy of Endometriosis.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
- Cuproptosis and cuproptosis-related cell death and genes: mechanistic links to spermatogenic cell death.Cell death discovery · 2025Review
- Identification of potential biomarkers of cuproptosis in cerebral ischemia.Frontiers in nutrition · 2024Article
- Roles of Dihydrolipoamide Dehydrogenase in Health and Disease.Antioxidants & redox signaling · 2023Review
- Extracellular matrix remodeling in tumor progression and immune escape: from mechanisms to treatments.Molecular cancer · 2023Review
- The pathogenesis of DLD-mediated cuproptosis induced spinal cord injury and its regulation on immune microenvironment.Frontiers in cellular neuroscience · 2023Article
- Molecular subtypes based on cuproptosis-related genes and tumor microenvironment infiltration characterization in ovarian cancer.Cancer cell international · 2022Article
- Pan-cancer analysis of cuproptosis regulation patterns and identification of mTOR-target responder in clear cell renal cell carcinoma.Biology direct · 2022Article
- Targeting 2-oxoglutarate dehydrogenase for cancer treatment.American journal of cancer research · 2022Review
- Cuproptosis-related gene signature stratifies lower-grade glioma patients and predicts immune characteristics.Frontiers in genetics · 2022Article
- The cuproptosis related genes signature predicts the prognosis and correlates with the immune status of clear cell renal cell carcinoma.Frontiers in genetics · 2022Article
- Dihydrolipoamide dehydrogenase, pyruvate oxidation, and acetylation-dependent mechanisms intersecting drug iatrogenesis.Cellular and molecular life sciences : CMLS · 2021Review
- Albumin Fusion at the N-Terminus or C-Terminus of HM-3 Leads to Improved Pharmacokinetics and Bioactivities.Biomedicines · 2021Article
- Proteomics Approach of Rapamycin Anti-Tumoral Effect on Primary and Metastatic Canine Mammary Tumor Cells In Vitro.Molecules (Basel, Switzerland) · 2021Article
- Review
- EGCG Promotes Neurite Outgrowth through the IntegrinEvidence-based complementary and alternative medicine : eCAM · 2021Article
- Cell Adhesion Molecules in Plasticity and Metastasis.Molecular cancer research : MCR · 2021Review
- Dihydrolipoamide dehydrogenase regulates cystine deprivation-induced ferroptosis in head and neck cancer.Redox biology · 2020Article
- Underlying molecular alterations in human dihydrolipoamide dehydrogenase deficiency revealed by structural analyses of disease-causing enzyme variants.Human molecular genetics · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cancer cells frequently exhibit higher levels of reactive oxygen species (ROS) than normal cells and when ROS levels increase beyond a cellular tolerability threshold, cancer cell death is enhanced. The mitochondrial dihydrolipoamide dehydrogenase (DLDH) is an enzyme which produces ROS in association with its oxidoreductive activity and may be thus utilized as an exogenous anticancer agent. As cancer cells often overexpress integrins that recognize RGD-containing proteins, we have bioengineered the human DLDH with RGD motifs (DLDH
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.